Table 1.
Baseline patients' characteristics.
| Characteristics | n (%) |
|---|---|
| Age, years | |
| Median (range) | 69 (39–84) |
| Gender | |
| Female | 12 (57.1) |
| Male | 9 (42.9) |
| Performance status | |
| 0–1 | 16 (76.2) |
| ≥2 | 5 (23.8) |
| Smoking status | |
| Never | 18 (85.7) |
| Smoker/former smoker | 3 (14.3) |
| Type of EGFR sensitizing mutation | |
| Exon 19 deletion | 18 (85.7) |
| L858R (exon 21) | 3 (14.3) |
| Stage | |
| IVA | 9 (42.9) |
| IVB | 12 (57.1) |
| Metastasis | |
| CNS | 3 (14.3) |
| Extra-thoracic | 13 (61.9) |
| Previous treatment | |
| 1 | 13 (61.9) |
| ≥2 | 8 (38.1) |
| Previous TKIs | |
| 1st generation (erlotinib/gefitinib) | 18 (85.7) |
| 2nd generation (afatinib) | 1 (4.8) |
| Sequential TKIs | 2 (9.5) |
CNS, central nervous system.